# Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy

**Authors:** Fernanda van Petten Vasconcelos Azevedo, Ana Lúcia Tasca Gois Ruiz, Diego Samuel Rodrigues, Douglas Hideki Nakahata, Raphael Enoque Ferraz de Paiva, Daniele Ribeiro de Araujo, Ana Carola de La Via, Wendel Andrade Alves, Michelle Barreto Requena, Cristina Kurachi, Mirian Denise Stringasci, José Dirceu Vollet-Filho, Wilton Rogério Lustri, Vanderlei Salvador Bagnato, Camilla Abbehausen, Pedro Paulo Corbi, Carmen Silvia Passos Lima

PMC · DOI: 10.3390/pharmaceutics18020145 · 2026-01-23

## TL;DR

This review explores innovative strategies and modeling techniques to improve metal-based drugs for skin cancer treatment, addressing challenges like poor solubility and skin permeability.

## Contribution

The paper provides a comprehensive overview of recent advances in metallopharmaceuticals and delivery systems for skin cancer, emphasizing predictive modeling and novel formulations.

## Key findings

- Metallopharmaceuticals show promise in inducing oxidative stress and modulating cancer pathways.
- Drug delivery systems like nanoparticles and microneedles enhance skin permeation and stability of metal complexes.
- Computational modeling supports the design of effective nanocarriers for targeted skin cancer therapy.

## Abstract

Skin cancer (SC) is the most prevalent malignancy worldwide, with subtypes varying in aggressiveness: basal cell carcinoma tends to be locally invasive, squamous cell carcinoma has a higher metastatic risk, and melanoma remains the deadliest form. Current treatments such as surgery, radiotherapy, and systemic chemotherapy are associated with aesthetic and functional morbidity, recurrence, and/or systemic toxicity. Although targeted therapies and immunotherapies offer clinical benefits, their high cost and limited accessibility underscore the need for innovative, affordable alternatives. Metal-based compounds (metallopharmaceuticals) are promising anticancer agents due to their ability to induce oxidative stress, modulate redox pathways, and interact with DNA. However, clinical translation has been limited by poor aqueous solubility, rapid degradation, and low skin permeability. This review discusses the most recent preclinical findings on gold, silver, platinum, palladium, ruthenium, vanadium, and copper complexes, mainly in topical and systemic treatments of SC. Advances in chemical and physical enhancers, such as hydrogels and microneedles, and in drug delivery systems, including bacterial nanocellulose membranes and nanoparticles, as well as liposomes and micelles, for enhancing skin permeation and protecting the integrity of metal complexes are also discussed. Additionally, we examine the contribution of photodynamic therapy to SC treatment and the use of mathematical and computational modeling to simulate skin drug transport, predict biodistribution, and support rational nanocarrier design. Altogether, these strategies aim to bridge the gap between physicochemical innovation and clinical applicability, paving the way for more selective, stable, and cost-effective SC treatments.

## Linked entities

- **Chemicals:** gold (PubChem CID 23985), silver (PubChem CID 23954), platinum (PubChem CID 23939), palladium (PubChem CID 23938), ruthenium (PubChem CID 23950), vanadium (PubChem CID 23990), copper (PubChem CID 23978)
- **Diseases:** skin cancer (MONDO:0002898), basal cell carcinoma (MONDO:0005341), squamous cell carcinoma (MONDO:0005096), melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, MITF (melanocyte inducing transcription factor) [NCBI Gene 4286] {aka CMM8, COMMAD, MI, MITF-A, WS2, WS2A}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, GLI1 (GLI family zinc finger 1) [NCBI Gene 2735] {aka GLI, PAPA8, PPD1}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, PTCH1 (patched 1) [NCBI Gene 5727] {aka BCNS, BCNS1, NBCCS, PTC, PTC1, PTCH}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, SMO (smoothened, frizzled class receptor) [NCBI Gene 6608] {aka CRJS, FZD11, Gx, PHLS, SMOH}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, MC1R (melanocortin 1 receptor) [NCBI Gene 4157] {aka CMM5, MSH-R, SHEP2}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, NOTCH2 (notch receptor 2) [NCBI Gene 4853] {aka AGS2, HJCYS, hN2}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, PRDX5 (peroxiredoxin 5) [NCBI Gene 25824] {aka ACR1, AOEB166, B166, HEL-S-55, PLP, PMP20}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, SUFU (SUFU negative regulator of hedgehog signaling) [NCBI Gene 51684] {aka BCNS2, JBTS32, PRO1280, SUFUH, SUFUXL}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, ACHE (acetylcholinesterase (Yt blood group)) [NCBI Gene 43] {aka ACEE, ARACHE, N-ACHE, YT}
- **Diseases:** B16 melanoma (MESH:D008546), pain (MESH:D010146), Hereditary melanoma (MESH:D009386), warts (MESH:D014860), MDR (MESH:D018088), mitochondrial dysfunction (MESH:D028361), infected skin lesion (MESH:D012871), injury to (MESH:D014947), inflammation (MESH:D007249), prostate cancer (MESH:D011471), Melanoma (MESH:D008545), Gorlin-Goltz syndrome (MESH:D005489), onychomycosis (MESH:D014009), AKs (MESH:D055623), Basal cell nevus syndrome (MESH:D001478), cervical adenocarcinoma (MESH:D000230), Cancer (MESH:D009369), skin carcinogenesis (MESH:D063646), cutaneous disorders (MESH:D018366), phototoxicity (MESH:D017484), cutaneous premalignant lesions (MESH:D009059), hypoxic (MESH:D002534), Basocellular skin carcinoma (MESH:D012878), SCC (MESH:D002294), head-and-neck squamous cell carcinoma (MESH:D000077195), cutaneous toxicities (MESH:D013262), burns (MESH:D002056), hyperthermia (MESH:D005334), psoriasis (MESH:D011565), deaths (MESH:D003643), leukemia (MESH:D007938), pythiosis (MESH:D058968), rheumatoid arthritis (MESH:D001172), lung metastases (MESH:D009362), erosions (MESH:D014077), infected wounds (MESH:D014946), cytotoxic (MESH:D064420), organ toxicity (MESH:D019965), infected (MESH:D007239), immune dysfunction (MESH:D007154), verrucous carcinoma (MESH:D018289), gastrointestinal malignancies (MESH:D005770), granuloma (MESH:D006099), phobia (MESH:D010698), cutaneous lymphoma (MESH:D008223), breast adenocarcinoma (MESH:D001943), sporotrichosis (MESH:D013174), glioblastoma (MESH:D005909), XP (MESH:D014983), nodular lesions (MESH:D020518), prostate carcinoma (MESH:D011472), hepatocellular carcinoma (MESH:D006528), erythema (MESH:D004890), acne (MESH:D000152), necrosis (MESH:D009336), BCC (MESH:D002280)
- **Chemicals:** 1-dodecylazacycloheptan-2-one (MESH:C035229), DTIC (MESH:D003606), sugar (MESH:D000073893), bacteriochlorins (MESH:C452433), zinc (MESH:D015032), oxygen (MESH:D010100), CNC (MESH:D000069449), stainless steel (MESH:D013193), clonidine (MESH:D003000), Metal (MESH:D008670), Platinum (MESH:D010984), vismodegib (MESH:C538724), lutetium (MESH:D008187), singlet oxygen (MESH:D026082), Au (MESH:D006046), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (MESH:C028694), triglycerides (MESH:D014280), esters (MESH:D004952), tulobuterol (MESH:C010809), NAMI-A (MESH:C113661), carbon (MESH:D002244), rhenium (MESH:D012211), vemurafenib (MESH:D000077484), DPPC (MESH:D015060), epinephrine hydrochloride (MESH:D004837), polymer (MESH:D011108), nitrogen dioxide (MESH:D009585), polysaccharide (MESH:D011134), Fe (MESH:C004998), tamoxifen (MESH:D013629), MOFs (MESH:D000073396), paclitaxel (MESH:D017239), PEG (MESH:D011092), nitrogen (MESH:D009584), V (MESH:D014639), catechol (MESH:C034221), Elesclomol (MESH:C512195), iron (MESH:D007501), auranofin (MESH:D001310), Iridium (MESH:D007495), panitumumab (MESH:D000077544), terpenes (MESH:D013729), Zinc oxide (MESH:D015034), L (MESH:D007930), water (MESH:D014867), Palladium (MESH:D010165), phospholipid (MESH:D010743), 5-FU (MESH:D005472), methylene blue (MESH:D008751), free radicals (MESH:D005609), CuCl2 (MESH:C029892), [Au(dppe)2]Cl (MESH:C050185), calcium peroxide (MESH:C403632), cyclohexane (MESH:C506365), NO (MESH:D009569), cholesterol (MESH:D002784), hemicellulose (MESH:C007916), (C-E) (MESH:D002563), ceramides (MESH:D002518), pyrimidine (MESH:C030986)
- **Species:** Rhizoclonium (genus) [taxon 162072], Alcaligenes (genus) [taxon 507], Mus musculus (house mouse, species) [taxon 10090], Novacetimonas hansenii (species) [taxon 436], Human immunodeficiency virus 1 (no rank) [taxon 11676], Rhizobium (genus) [taxon 379], Chaetomorpha (genus) [taxon 3185], Danio rerio (leopard danio, species) [taxon 7955], Human immunodeficiency virus (species) [taxon 12721], Homo sapiens (human, species) [taxon 9606], Pseudomonas (RNA similarity group I, genus) [taxon 286], Newcastle disease virus [taxon 11176]
- **Mutations:** Rs7623610, A2920C, Rs16944, T30028C, Ile105Val, Rs10932201, Rs4141134, Arg72Pro
- **Cell lines:** WM1158 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_6785), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), B16 melanoma — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_F936), 22Rv1 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_1045), NCI-ADR/RES — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_1452), /6 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_5985), B16-F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), FaDu — Homo sapiens (Human), Hypopharyngeal squamous cell carcinoma, Cancer cell line (CVCL_1218), 786-O — Homo sapiens (Human), Renal cell carcinoma, Cancer cell line (CVCL_1051), NCI-H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), U84-MG — Homo sapiens (Human), Plasma cell myeloma, Cancer cell line (CVCL_0016), UACC-62 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_1780), K562 — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0004), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), /6N — Mus musculus (Mouse), Transformed cell line (CVCL_D461), MRC-5 — Homo sapiens (Human), Finite cell line (CVCL_0440), SCC15 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_1681), Balb/C — Mus musculus (Mouse), Mouse thymic lymphoma, Cancer cell line (CVCL_C5SS), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), MO59J — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0400), J774A.1 — Mus musculus (Mouse), Mouse reticulum cell sarcoma, Cancer cell line (CVCL_0358), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), ME1402 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_C672), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), A431 — Homo sapiens (Human), Skin squamous cell carcinoma, Cancer cell line (CVCL_0037), U251 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0021), A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0132), CN-mel — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_7037), SK-Mel28 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_0526), V79 — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_2234), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_JX14), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320)

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943739/full.md

---
Source: https://tomesphere.com/paper/PMC12943739